You are here: Industry Insights > Sacituzumab Govitecan

News List

Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer prnasia
January 04, 2022
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia...
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...
Experimental Drug Helps Women With Deadly Type of Breast Cancer drugs
February 21, 2019
An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial....
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer firstwordpharma
November 09, 2018
Phase 2 Platform Study to Evaluate the Combination of Imfinzi® (Durvalumab) and Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer Who Progressed
Seattle Genetics Announces Agreement with Immunomedics for Sacituzumab Govitecan, a Promising Late-S americanpharmaceuticalreview
February 13, 2017
Seattle Genetics has announced a development and license agreement with Immunomedics, Inc.